Revved-up Tecfidera sales power Biogen in Q4

Eric Palmer Biogen CEO George Scangos and his team tamped down investor expectations earlier this month at the J.P. Morgan Healthcare Conference, saying that the company faced headwinds. ...

J&J’s new launches deliver, but overall sales fall short on hep C, strong dollar

Carly Helfand Johnson & Johnson's hep C sales have been nosediving, and the fourth quarter provided more of the same on that front. But in the quarter, a strong dollar ...

Takeda doubles U.K. rep ranks to boost oncology, IBD sales

Carly Helfand Takeda has its eye on some serious growth–and to help it get there, it's bringing its U.K. sales force in-house. Beginning this June, 70 contract staffers–including ...

Stepped-up Nucynta sales push starts paying off for Depomed

Tracy Staton Depomed's relaunch of the Nucynta franchise–purchased earlier this year from Johnson & Johnson–is off to a running start, the company said last week ...

Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast

Eric Palmer The speed bump that sales of Biogen's Tecfidera hit earlier this year, slowing its growth, has turned into a big old pothole and it has shaken investors pretty hard ...

Actavis delivers big Q1 sales boost, thanks to Forest, Allergan buys

Emily Wasserman Spring is in the air, and Actavis is starting to see the fruits of last year's M&A. The company reported first-quarter earnings that beat expectations–and ...

Pfizer shutters vaccine sales business in China after Prevenar setback

Carly Helfand As it beefs up its vaccines business, Pfizer's looking to bolster revenue from the top-selling Prevenar family of shots. But on that front, it's come up against ...

FDA grants Celgene’s Revlimid new use as it moves toward $10B in sales

Eric Palmer Celgene's powerhouse cancer drug Revlimid generated nearly $ 5 billion for the company last year and has now gotten yet another FDA nod which analysts believe will ...

Shooting for $5B in sales, India’s Lupin says it can actually hit U.S. launch goal this year

EJ Lane SINGAPORE–Despite missing its target for bringing 15 to 20 drugs to the U.S. market last year, Lupin is optimistic enough about 2015 that it seeks possible acquisitions ...

Salix expects lackluster sales as it speeds to fix inventory issues

Carly Helfand Back in November, Salix revealed some inventory issues that had skewed perceived demand for some of its products–and possibly cost it a deal with Allergan in the ...

Can J&J score sales with FDA’s new Olysio-plus-Sovaldi approval?

Tracy Staton Johnson & Johnson just scored a marketing goal: Its hepatitis C drug Olysio won FDA approval as part of a two-drug cocktail that also stars Gilead Sciences' Sovaldi. ...

Sanofi’s U.S. sales team gets its close-up–and a promised makeover

Tracy Staton Sanofi's U.S. diabetes sales team is under a worldwide spotlight–and not because it's time to take a bow. FiercePharma News
Page 1 of 912345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS